TY - JOUR
T1 - Effectiveness of 5% Topical Imiquimod for Lentigo Maligna Treatment
AU - Tio, Darryl C. K. S.
AU - van Montfrans, Catherine
AU - Ruijter, Claire G. H.
AU - Hoekzema, Rick
AU - Bekkenk, Marcel W.
PY - 2019
Y1 - 2019
N2 - Lentigo maligna (LM) is treated to prevent progression to lentigo maligna melanoma (LMM). Surgery is the gold standard but an alternative treatment is off-label topical imiquimod. The aim of this study was to evaluate the effectiveness of 5% topical imiquimod treatment for lentigo maligna. In the period 2007-2017 57 patients with lentigo maligna were treated with off-label topical imiquimod once daily for 12 weeks. Complete clinical clearance was observed in 48 patients (84.2%) and partial clearance in 3 patients (5.3%). Three patients (5.3%) showed no response and another 3 patients (5.3%) stopped treatment due to side-effects. After 4.5 years during follow-up one patient developed a lentigo maligna melanoma which was subsequently excised. Treatment with topical imiquimod resulted in complete clearance of lentigo maligna in 48 out of 57 patients (84.2%). Topical imiquimod is an acceptable treatment option for patients with lentigo maligna who prefer topical treatment to surgery or radiotherapy.
AB - Lentigo maligna (LM) is treated to prevent progression to lentigo maligna melanoma (LMM). Surgery is the gold standard but an alternative treatment is off-label topical imiquimod. The aim of this study was to evaluate the effectiveness of 5% topical imiquimod treatment for lentigo maligna. In the period 2007-2017 57 patients with lentigo maligna were treated with off-label topical imiquimod once daily for 12 weeks. Complete clinical clearance was observed in 48 patients (84.2%) and partial clearance in 3 patients (5.3%). Three patients (5.3%) showed no response and another 3 patients (5.3%) stopped treatment due to side-effects. After 4.5 years during follow-up one patient developed a lentigo maligna melanoma which was subsequently excised. Treatment with topical imiquimod resulted in complete clearance of lentigo maligna in 48 out of 57 patients (84.2%). Topical imiquimod is an acceptable treatment option for patients with lentigo maligna who prefer topical treatment to surgery or radiotherapy.
KW - Lentigo maligna
KW - Melanoma
KW - Topical imiquimod
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85071714931&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/31233181
U2 - 10.2340/00015555-3241
DO - 10.2340/00015555-3241
M3 - Article
C2 - 31233181
VL - 99
SP - 884
EP - 888
JO - Acta dermato-venereologica
JF - Acta dermato-venereologica
SN - 0001-5555
IS - 10
ER -